Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMGN632 |
Synonyms | |
Therapy Description |
IMGN632 is an antibody-drug conjugate comprised of an anti-CD123 antibody linked to a DNA alkylating agent, an indolinobenzodiazepine pseudodimer, which may result in cytotoxicty of cells expressing CD123 (PMID: 29661755, PMID: 30361418). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMGN632 | IMGN 632|IMGN-632 | IMGN632 is an antibody-drug conjugate comprised of an anti-CD123 antibody linked to a DNA alkylating agent, an indolinobenzodiazepine pseudodimer, which may result in cytotoxicty of cells expressing CD123 (PMID: 29661755, PMID: 30361418). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03386513 | Phase Ib/II | IMGN632 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT04086264 | Phase Ib/II | IMGN632 IMGN632 + Venetoclax Azacitidine + IMGN632 Azacitidine + IMGN632 + Venetoclax | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 0 |